Core Viewpoint - The company, Si Rui Pu Microelectronics Technology (Suzhou) Co., Ltd., has adjusted the internal investment structure of certain fundraising projects to optimize the use of raised funds while ensuring compliance with relevant regulations [1][5]. Fundraising Basic Situation - The company raised a total of RMB 1,800,998,982.47 through the issuance of 12,044,399 A-shares, with all funds received by October 23, 2023 [1][2]. - A special account for managing the raised funds has been established, ensuring compliance with regulations and protecting investor rights [2]. Fundraising Investment Project Situation - The net amount of raised funds is allocated to various projects, with a total planned investment of RMB 433,006.29 million for the high-integration analog front-end and mixed-signal product R&D and industrialization project [2][3]. - The adjusted investment amount for the high-integration analog front-end and mixed-signal product R&D and industrialization project is now RMB 178,165.66 million [2][4]. Specific Adjustments to Investment Structure - The internal investment structure for the high-integration analog front-end and mixed-signal product R&D and industrialization project and the testing center construction project has been adjusted, with specific changes in R&D expenses and equipment costs [4][5]. - The adjustments include an increase in R&D expenses from RMB 15,465.39 million to RMB 22,175.39 million, while soft and hardware equipment costs have been reduced [4]. Impact of Adjustments - The adjustments are expected to optimize the investment structure and ensure the smooth implementation of fundraising projects without adversely affecting the company's normal operations [5][6]. - The overall investment scale and fund usage remain unchanged, ensuring compliance with legal regulations and alignment with the company's long-term development plan [5][6]. Review Procedures and Opinions - The adjustments were approved by the company's board of directors and supervisory board, confirming that the decision-making process adhered to relevant regulations [5][6]. - The sponsor, Guotai Junan Securities Co., Ltd., has no objections to the adjustments, affirming that they do not alter the intended use of funds or harm shareholder interests [6].

国泰海通证券股份有限公司 关于合肥新汇成微电子股份有限公司 员工借款管理办法的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 合肥新汇成微电子股份有限公司（以下简称"汇成股份"或"公司"）首次公开 发行股票并上市及向不特定对象发行可转换公司债券的保荐机构，根据《证券发 行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》 《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》和《上海证券交易所上市公司 自律监管指引第 11 号——持续督导》等法律法规的相关规定，对公司制定《合 肥新汇成微电子股份有限公司员工借款管理办法》 （以下简称" 《员工借款管理办 法》 "）的相关事项进行了核查，核查情况及核查意见如下： 《员工借款管理办法》的目的及适用范围 （一）目的 为更好的吸引与留住优秀人才，解决员工在生活中遇到的临时性资金困难， 应对短期资金需求，以提升员工福利与归属感，促进公司与员工共同发展。 （二）适用范围 公司（含合并报表范围内各级子公司）中高层管理人员（不包含高级管理人 员）及有特殊贡献人员适用本办法； 《员工借款管理办法》全文同日在上海证券交易所网站（ww ...

依据《上海证券交易所公司债券上市规则》等规定，上交所同意国泰海通证券股份有限公司2025年面向 专业投资者公开发行公司债券（第四期）（品种二）于2025年8月26日起在上交所上市，并采取匹配成 交、点击成交、询价成交、竞买成交、协商成交交易方式。该债券证券简称为"25GTHT08"，证券代码 为"243545"。根据中国结算规则，可参与质押式回购。 8月25日，上交所发布关于国泰海通证券股份有限公司2025年面向专业投资者公开发行公司债券（第四 期）（品种二）上市的公告。 来源：金融界 ...

8月25日，上交所发布关于国泰海通证券股份有限公司2025年面向专业投资者公开发行公司债券（第四 期）（品种一）上市的公告。 依据《上海证券交易所公司债券上市规则》等规定，上交所同意国泰海通证券股份有限公司2025年面向 专业投资者公开发行公司债券（第四期）（品种一）于2025年8月26日起在上交所上市，并采取匹配成 交、点击成交、询价成交、竞买成交、协商成交交易方式。该债券证券简称为"25GTHT07"，证券代码 为"243544"。根据中国结算规则，可参与质押式回购。 来源：金融界 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management to improve fund efficiency and increase returns for the company and its shareholders [6][9][10]. Summary by Sections Fundraising Overview - The company raised a total of RMB 75,880.00 million from its initial public offering (IPO) in August 2020, with a net amount of RMB 68,955.19 million after deducting issuance costs [1]. - In November 2023, the company raised RMB 18,830.26 million through a targeted issuance of shares, resulting in a net amount of RMB 18,342.53 million after expenses [2]. Investment Projects - The company disclosed that the funds from the IPO were allocated to a high-precision small power testing power supply and fuel cell, power semiconductor testing equipment production base construction project, with a planned use of RMB 27,646.23 million [3]. - The company has excess funds of RMB 41,308.96 million from the IPO, with plans to allocate the surplus to various projects, including a semiconductor testing and intelligent manufacturing equipment industrial park project [3][4]. Cash Management of Idle Funds - The company intends to use up to RMB 23,000 million of temporarily idle raised funds for cash management, with RMB 20,000 million from the IPO and RMB 3,000 million from the 2023 issuance [7][10]. - The cash management will involve investing in low-risk, high-liquidity financial products, ensuring that the funds are not used for non-raising purposes [7][8]. Board Approval and Compliance - The board of directors approved the cash management plan on August 22, 2025, ensuring that it does not affect the progress of investment projects or the safety of the raised funds [10]. - The company has complied with relevant regulations and internal policies regarding the management and use of raised funds, ensuring that the cash management does not alter the intended use of the funds [11].

Core Viewpoint - The company has completed the investment project of the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park" and plans to permanently supplement its working capital with the remaining raised funds, following the completion of the project and the approval of the board and shareholders [6][9][10]. Fundraising Overview - The company raised a total of RMB 758.8 million from its initial public offering, with a net amount of RMB 689.55 million after deducting issuance costs [1]. - The company established a special account for the management and use of the raised funds, ensuring compliance with regulatory requirements [2]. Investment Project Details - The company committed to invest RMB 276.46 million in the "High-Precision Small Power Testing Power Supply and Fuel Cell, Power Semiconductor Testing Equipment Production Base Construction Project" [2]. - The actual net amount raised was RMB 689.55 million, resulting in an excess of RMB 413.09 million after the planned investment [3]. Use of Excess Funds - The company decided to use RMB 120 million of the excess funds to permanently supplement working capital, which constitutes approximately 29.05% of the total excess funds [3][4]. - The remaining excess funds will be allocated to the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park Project," with a total investment of RMB 450 million, of which RMB 300 million will come from excess funds [4][5]. Project Completion and Surplus Funds - As of July 31, 2025, the project has completed its main construction and acceptance work, leading to the decision to conclude the project [6]. - The expected surplus funds amount to RMB 168.27 million, which includes interest and investment income, and will be used to permanently supplement working capital [8][9]. Impact on Company Operations - The decision to conclude the project and use surplus funds for working capital is aligned with the company's operational needs and long-term development strategy, enhancing cash flow and resource allocation [9][10]. - The company will maintain the special account for raised funds until all pending payments are settled, ensuring compliance with regulatory requirements [9]. Approval Process - The board of directors approved the proposal to conclude the investment project and use surplus funds on August 22, 2025, which will also require shareholder approval [10]. - The sponsor institution has confirmed that the decision complies with relevant regulations and is in the best interest of all shareholders [10][11].

国泰海通证券股份有限公司 关于中巨芯科技股份有限公司 首次公开发行部分战略配售限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 中巨芯科技股份有限公司（以下简称"中巨芯"或"公司"）首次公开发行股票 并在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规的相关规定，对中巨芯首次公开发行 部分战略配售限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2023 年 6 月 13 日出具的《关于同意中巨芯 （证监许可〔2023〕1278 号）， 科技股份有限公司首次公开发行股票注册的批复》 同意公司首次公开发行股票的注册申请，并经上海证券交易所同意，公司首次向 社会公开发行人民币普通股（A 股）股票 369,319,000 股，并于 2023 年 9 月 8 日 在上海证券交易所科创板上市，发行后公司总股本为 1,477,276,000 股，其中有 限售条件流通股 1,215 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 调整2025年度部分日常关联交易预计额度的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务 管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等相关法律、法规和规范性文件的 规定，对奥浦迈调整 2025 年度部分日常关联交易预计额度的的事项进行了专项 核查，核查情况与意见如下： 一、本次日常关联交易执行及调整情况 公司于 2025 年 4 月 14 日召开第二届董事会第八次会议、第二届监事会第 七次会议以及第二届董事会独立董事专门会议第二次会议分别审议通过了《关 于预计 2025 年度日常关联交易的议案》，同意公司（含子公司）对 2025 年度日 常关联交易额度进行预计，涉及金额合计 446.00 万元，主要用于向相关关联方 购买原材料、向关联方销售商品以及接受关联方提供的技术服务。关联董事肖 志华、张俊杰回避表决，获 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等法律法规的相关规定，对奥浦迈首次 公开发行部分限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 6 月 13 日出具的《关于同意上海奥浦迈生物科技股份有限公司首次公开发行股票注册的 批复》（证监许可〔2022〕1232 号），同意上海奥浦迈生物科技股份有限公司 （以下简称"奥浦迈"或者"公司"）首次公开发行股票的注册申请，并经上海证券 交易所同意，公司首次向社会公众公开发行人民币普通股 2,049.5082 万股，并于 本为 8,198.0328 万股，其中，有限售条件流通股 6,50 ...

Summary of Key Points Core Viewpoint The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and maximize shareholder returns while ensuring compliance with regulations and maintaining the intended use of the raised funds [1][7]. Group 1: Fundraising and Management - The company raised a total of RMB 1,643,705,576.40 through its initial public offering, with a net amount after expenses being RMB 1,643,705,576.40 [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Group 2: Cash Management Plan - The company plans to use up to RMB 70,000.00 million of temporarily idle raised funds for cash management, with a rolling usage period of 12 months [3][4]. - The investment products will include safe and liquid options such as fixed deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [4]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not affect the normal operation of the fundraising projects [5][6]. - The supervisory board supports the plan, stating it will not harm the interests of the company or its shareholders [6]. Group 4: Compliance and Risk Management - The cash management activities are in compliance with relevant regulations and internal management systems, ensuring no change in the intended use of the raised funds [7]. - The company will implement strict risk control measures, focusing on high-security and high-liquidity investment products, while monitoring market conditions [5].